MPNCo&D Program

Friday, October 6, 2023
07:45-08:00 Welcome Coffee
08:00-09:00 Industry-supported Morning Symposium
09:00-09:15 Technical Break
09:15-10:45 Session 1: Polycythemia Vera in 2023 and beyond
Moderators: Naveen Pemmaraju, USA; Claire Harrison, UK & Ruben Mesa, USA
Debate: Standard of care in PV
09:15-09:25 Thrombosis/risk stratification in PV – aiming for a normal PBC: Mary Frances McMullin, UK
09:25-09:35 IFN in PV – with molecular monitoring: Jean-Jacques Kiladjian, France
09:35-09:50 PTG-300/Rusfertide: from bench to bedside – Hepcidin Mimetics in PV: Ronald Hoffman, USA
Debate: All PV patients should be treated
09:50-10:00 Yes, including lower-risk: Tiziano Barbui, Italy
10:00-10:10 No, only higher risk: Ruben Mesa, USA
10:10-10:25 Should we still use HU for PV – can RUX go to the front line? Claire Harrison, UK
10:25-10:45 Roundtable discussion: All session faculty
10:45-11:15 Coffee Break
11:15-12:45 Session 2: Essential thrombocytosis – Can we do better?
Moderators: Claire Harrison, UK; Anna Godfrey, UK
11:15-11:35 Higher risk ET: state-of-the-art management in 2023: Claire Harrison, UK
11:35-11:50 What is my approach to triple negative thrombocytosis? Anna Godfrey, UK
11:50-12:10 Should all patients with ET have aspirin? Tiziano Barbui, Italy
12:00-12:30 CALR: role of immunotherapy as future directions/novel approaches: Bethan Psaila, UK
12:30-12:45 Roundtable discussion: All session faculty
12:45-13:00 Lunch Box pick-up and Break
13:00-14:30 Industry-supported Lunch Symposium
14:30-14:45 Technical Break
14:45-16:15 Session 3: Myelofibrosis: current and novel approaches in a rapidly developing field
Moderators: Naveen Pemmaraju, USA; John Mascarenhas, USA
14:45-15:00 Pre-fibrotic MF: a new entity with special considerations: Paola Guglielmelli, Italy
15:00-15:15 Early/lower risk MF: treatment options and approach: Ruben Mesa, USA
15:15-15:30 Int/higher risk MF: current treatment options in 2023: John Mascarenhas, USA
15:30-15:45 Current data for combinations for JAKi naïve patients: Naveen Pemmaraju, USA
15:45-16:00 Clinical and molecular factors, biomarkers of MPN progression: current and future: Adam Mead, UK
16:00-16:15 Anemia in MF: an emerging area for novel approaches: Naveen Pemmaraju, USA
16:15-16:45 Coffee Break
16:45-18:15 Session 4: Treatment of high-risk MF
Moderators: Florian Heidel, Germany; John Mascarenhas, USA
16:45-17:00 How to define failure of JAKi: Florian Heidel, Germany
17:00-17:15 Current outcomes for transplantation in MF: Maria Robin, France
Debate: Future directions: Transplantation in MPN
17:15-17:25 Transplant early before patients fail a JAKi: Donal McLornan, UK
17:25-17:35 Patients failing a JAKi can be salvaged without BMT: John Mascarenhas, USA
17:35-17:50 Novel agents in the clinic beyond JAKi: Raajit Rampal, USA
17:50-18:15 Roundtable discussion: All session faculty
Saturday, October 7, 2023
09:15-11:00 Session 5: AYA MPNs: pregnancy, thromboses and special considerations
Moderators: Isabelle Plo, France; Ruben Mesa, USA
09:15-09:30 New data for thrombosis in MPN: Anna Falanga, Italy
09:30-09:45 Gastro-oncology: splanchnic vein thrombosis a primer for haematologists: David Patch, UK
09:45-10:00 Cardio-oncology: primer on intersection of cardio-oncology and MPNs: arrythmias, clots, anticoagulation and cardiac considerations: Michael Fradley, USA
10:00-10:15 Pregnancy, fertility and hormone therapy: state-of-the-art considerations: Susan Robinson, UK
10:15-10:30 Young patients with MPNs: unique considerations in thromboses: Jean-Christophe Ianotto, France
10:30-10:45 Latest update on inheritability and MPN: Isabelle Plo, France
10:45-11:00 Roundtable discussion: All session faculty
10:45-11:15 Coffee Break
11:15-12:45 Session 6: Rare MPNs – Focus on emerging subtypes
Moderators: Deepti Radia, UK; Andreas Reiter, Germany
11:15-11:30 Investigation and management of eosinophilia: Andreas Reiter, Germany
11:30-11:45 Aggressive SM: emerging therapy options: Deepti Radia, UK
11:45-12:00 Current management of CMML: Eric Solary, France
12:00-12:15 Investigation and management of congenital erythrocytosis: Mary Frances McMullin, UK
12:15-12:45 Roundtable discussion: All session faculty
12:45-13:00 Lunch Box pick-up and Break
13:00-14:30 Industry-supported Lunch Symposium
14:30-14:45 Technical Break
14:45-16:15 Session 7: Current and future considerations in MPNs and rare hematologic malignancies: building innovative, sustainable programs across the world
Moderators: Naveen Pemmaraju, USA; Ruben Mesa, USA
14:45-15:00 Special lecture: The Patient Experience: reflections from an MPN patient and advocate for what every clinical provider should know: Jonathan Mathias, UK
15:00-15:15 What advocacy networks exist in MPN and how can we work together to achieve their ambitions? Werner Zinkand, Germany
15:15-15:30 Future directions in MPN: AI and MPN: Daniel Royston, UK
15:30-15:45 How to conduct and publish RWE studies in MPN: TBA
15:45-16:00 CHIP and MPNs: what have we learned from population studies in Denmark? Hans Hasselbalch, Denmark
16:00-16:15 Plenary closing lecture: MPNs and Targeting stem cells in MF: Past, Present and Future: Ronald Hoffman, USA

Registration

Register for the Joint IACH Meeting 2023